Global Oncology trial activity and complexity levels are higher than pre-pandemic, even as counts of planned trial sites and countries have declined. At the same time, timelines for site enrollment have lengthened by 19% since 2019 and time for new therapeutics to reach patients has also increased. Europe has lost significant share of the global oncology industry-sponsored interventional trial activity over past five years, primarily to the U.S., China, and Australia. Efforts to restore and strengthen Europe’s contribution to oncology clinical research have been underway for some time and provide important platforms for future progress. Investment, commitment and collaboration will be required to increase Europe’s level of trial activity over the next five years.
Join the IQVIA Institute and a multi-stakeholder panel in-person or virtually for a conversation on this important topic.
Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.
Oncology Expertise that Fuels Your Development Success
Unravel the complexities of cancer treatment with patient-level data-driven solutions.
.svg){kind=icon}
